Multiple myeloma often develops from the precursor condition monoclonal gammopathy of undetermined significance (MGUS), which is detectable in peripheral blood. ...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
Autologous stem cell transplantation (ASCT) is commonly used in the treatment of multiple myeloma, though relapse is extremely common. Ixazomib ...
1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates ...
1. The use of lenalidomide, bortezomib and dexamethasone (RVD) with transplantation was associated with a significantly longer progression-free survival compared ...
![Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/02/20541_lores-350x250.jpg)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Daratumumab is a human monoclonal antibody that has shown efficacy and safety in ...
1. The addition of daratumumab to standard therapy of lenalidomide and dexamethasone increased progression-free survival in relapsed or refractory multiple ...
1. Addition of daratumumab to bortezomib and dexamethasone increased the rate and length of progression-free survival. 2. The rates of ...
1. Adding the proteasome inhibitor Ixazomib to lenalidomide and dexamethasone significantly increased progression-free survival compared to lenalidomide and dexamethasone ...
